🔥Telegram İfşa

We look forward to sharing the final data from our Phase 2 combination study of casdozo with standard of care in patients with liver cancer with the medical community at the 2025 ASCO-GI annual meeting. Read more about our upcoming presentation: bit.ly/3ZHSnST

Today, we announced our attendance at the upcoming J.P. Morgan Healthcare Conference. Denny Lanfear, CEO, will be presenting on January 13th. Head to our website or read today’s press release for full presentation information: bit.ly/3C3nv7n #JPM25

We look forward to Dr. Denang Li’s presentation of the final data from our Phase 2 combination study of casdozo with standard of care in patients with liver cancer on Friday at the #ASCOGI bit.ly/3PL5myo $CHRS

Coherus will report Q4 and Full Year 2024 financial results on March 10, 2025. Starting at 5 pm EST, CHRS executive team will host a conference call and webcast to discuss Q4-FY 2024 financial results and recent business highlights. Webcast: bit.ly/4hlVgQ9

Join us for our Q4-FY 2024 earnings call today, starting at 5:00 pm ET, to hear about our Q4 financial results and recent business highlights. Press release: bit.ly/41DvYa7and Listen to the webcast: bit.ly/4hlVgQ9

We look forward to presenting interim data from our Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and with toripalimab in patients with HNSCC at the 2025 AACR Annual Meeting. For details: bit.ly/41IWvnO

Breaking News: Coherus completes strategic transformation with successful divestiture of UDENYCA® franchise. Read our press release for more: bit.ly/3XWNZ2d

Coherus will report Q1 2025 financial results on May 12, 2025. Starting at 5 pm EDT, $CHRS executive team will host a conference call and webcast to discuss Q1 2025 financial results and recent business highlights. Webcast: bit.ly/3EOEHyY

Join us for our Q1 2025 earnings call today, starting at 5:00 p.m. ET, to hear about our Q1 financial results and business highlights. Read our press release: bit.ly/4dob708 and listen to the webcast: bit.ly/3EOEHyY $CHRS

Starting today, we are now Coherus Oncology, Inc. Our new name better reflects our strategic transformation to focus exclusively on innovative cancer therapeutics. Read more here: bit.ly/3SsBGHO

Attending #ASCO25? Come by Booth #11081 this weekend to meet the Coherus team and learn more about our products and innovative immuno-oncology pipeline.

Coherus Oncology will report Q2 2025 financial results on August 7, 2025. Starting at 5 pm EDT, the $CHRS executive team will host a conference call and webcast to discuss Q2 2025 financial results and recent business highlights. Webcast: bit.ly/4fgZxVu

Join us for our Q2 2025 earnings call today, starting at 5:00 p.m. ET, to hear about our Q2 financial results and business highlights. Press release: bit.ly/4mBp0vl and listen to the webcast: bit.ly/4fgZxVu

Coherus Oncology is attending the following Fall Investor Conferences. For webcast links of our presentations, please visit: bit.ly/4nhV8EB To schedule 1x1 meetings during the conferences, please reach out to your respective bank representative.

Coherus Oncology’s CEO, Denny Lanfear, and Chief Scientific and Development Officer, Theresa LaVallee, are participating in a fireside chat with Colleen Kusy at the Baird 2025 Global Healthcare Conference today. Listen to the webcast here: bit.ly/3Ie3UV6

Coherus Oncology’s CEO, Denny Lanfear, and Chief Scientific and Development Officer, Theresa LaVallee, are participating in a fireside chat with Douglas Tsao at the H.C. Wainwright 27th Annual Global Investment Conference today. Listen to the webcast here: bit.ly/46sQtdc

We’re proud to have partnered with NORD and Rep Mike Kelly (PA) to introduce a resolution recognizing Sept 30th as Rare Cancer Day. Join us in supporting patients & families affected by a cancer diagnosis, including those with a rare form. Learn more: bit.ly/4gJMvR8

Tune in tomorrow for our fireside chat at UBS’s Virtual Oncology Day. We will discuss the latest developments with our novel oncology pipeline targeting the immune-suppressive mechanisms in the TME. Listen to the webcast: bit.ly/4mCSzvR

We look forward to sharing new biomarker data from our Phase 1 study of CHS-114 at the 40th Annual SITC Meeting in November. Read more about our presentation and upcoming SITC webinar: bit.ly/3VJT1h5

We are excited to participate in SITC’s Targets for Cancer IO webinar and discuss CCR8 as a therapeutic target in oncology and share our clinical experience with CHS-114, our highly selective cytolytic anti-CCR8 mAb. Register to attend: bit.ly/3VEkGjx